Opus Genetics (IRD) Competitors $1.18 -0.03 (-2.48%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.69%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD vs. ZYBT, ACB, SCPH, INZY, VOR, ANNX, AARD, NBTX, IMMP, and SOPHShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Zhengye Biotechnology (ZYBT), Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Inozyme Pharma (INZY), Vor Biopharma (VOR), Annexon (ANNX), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), Prima BioMed (IMMP), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Zhengye Biotechnology Aurora Cannabis scPharmaceuticals Inozyme Pharma Vor Biopharma Annexon Aardvark Therapeutics Nanobiotix Prima BioMed SOPHiA GENETICS Opus Genetics (NASDAQ:IRD) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Do analysts prefer IRD or ZYBT? Opus Genetics currently has a consensus price target of $7.33, indicating a potential upside of 521.47%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders believe in IRD or ZYBT? 15.0% of Opus Genetics shares are held by institutional investors. 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is IRD or ZYBT more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Opus Genetics' net margin of -429.42%. Zhengye Biotechnology's return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-429.42% -283.28% -144.32% Zhengye Biotechnology N/A N/A N/A Does the media refer more to IRD or ZYBT? In the previous week, Opus Genetics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.87 beat Opus Genetics' score of 0.62 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Opus Genetics Positive Zhengye Biotechnology Very Positive Which has better earnings and valuation, IRD or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Opus Genetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M6.41-$57.53M-$2.10-0.56Zhengye Biotechnology$25.53M10.25$1.55MN/AN/A SummaryZhengye Biotechnology beats Opus Genetics on 7 of the 13 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.19M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.5621.0428.0720.05Price / Sales6.41284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book5.628.378.665.87Net Income-$57.53M-$55.19M$3.25B$258.55M7 Day Performance4.42%5.89%4.20%2.23%1 Month Performance21.62%17.63%10.82%12.76%1 Year PerformanceN/A5.09%34.70%19.36% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.6496 of 5 stars$1.18-2.5%$7.33+521.5%N/A$72.19M$10.99M-0.5614ZYBTZhengye BiotechnologyN/A$5.69flatN/AN/A$268.38M$25.53M0.00278Positive NewsGap UpACBAurora Cannabis0.2778 of 5 stars$4.70+3.8%N/A-16.5%$264.36M$343.29M42.731,130SCPHscPharmaceuticals4.3958 of 5 stars$5.13+3.8%$14.00+172.9%+20.7%$260.79M$41.98M-2.6930News CoverageINZYInozyme Pharma2.7992 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750VORVor Biopharma3.8804 of 5 stars$2.05-7.2%$5.63+174.6%+129.7%$256.17MN/A-1.24140ANNXAnnexon2.456 of 5 stars$2.47+6.5%$12.50+406.1%-58.1%$254.54MN/A-2.0960AARDAardvark TherapeuticsN/A$12.00+3.3%$33.00+175.0%N/A$252.11MN/A0.0018NBTXNanobiotix1.6198 of 5 stars$5.11-3.6%$8.00+56.6%+22.0%$249.81M$39.18M0.00100News CoverageGap UpIMMPPrima BioMed1.4938 of 5 stars$1.71+0.6%$7.00+309.4%-19.0%$248.27MN/A0.002,021News CoveragePositive NewsUpcoming EarningsSOPHSOPHiA GENETICS2.5693 of 5 stars$3.49-6.2%$7.00+100.6%-21.9%$248.08M$65.17M-3.49520 Related Companies and Tools Related Companies Zhengye Biotechnology Alternatives Aurora Cannabis Alternatives scPharmaceuticals Alternatives Inozyme Pharma Alternatives Vor Biopharma Alternatives Annexon Alternatives Aardvark Therapeutics Alternatives Nanobiotix Alternatives Prima BioMed Alternatives SOPHiA GENETICS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts